{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T13:03:28Z","timestamp":1763125408506,"version":"3.45.0"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>\n                    A 61-year-old woman diagnosed with breast cancer and bone metastases underwent a\n                    <jats:sup>68<\/jats:sup>\n                    Ga-labeled DOTA-ibandronic acid (\n                    <jats:sup>68<\/jats:sup>\n                    Ga-DOTA-IBA) PET\/CT examination to evaluate the feasibility of\n                    <jats:sup>177<\/jats:sup>\n                    Lu-DOTA-IBA therapy. The\n                    <jats:sup>68<\/jats:sup>\n                    Ga-DOTA-IBA PET\/CT scan revealed multiple bone metastases throughout the body. Incidentally, the uptake of\n                    <jats:sup>68<\/jats:sup>\n                    Ga-DOTA-IBA was increased in the left axillary lymph node metastases and meningeal metastases.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006066","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T03:00:08Z","timestamp":1753844408000},"page":"1221-1223","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Increased Uptake of 68Ga-DOTA-IBA in Lymph Node and Meningeal Metastases of Breast Cancer"],"prefix":"10.1097","volume":"50","author":[{"given":"Na","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province"},{"name":"Laboratory for Targeted Radiopharmaceuticals Creation"},{"name":"Institute of Nuclear Medicine, Southwest Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Affiliated Hospital of Southwest Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huailin","family":"He","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huipan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province"},{"name":"Laboratory for Targeted Radiopharmaceuticals Creation"},{"name":"Institute of Nuclear Medicine, Southwest Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4088-7649","authenticated-orcid":false,"given":"Yue","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province"},{"name":"Laboratory for Targeted Radiopharmaceuticals Creation"},{"name":"Institute of Nuclear Medicine, Southwest Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"key":"R1-20251114","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1186\/s12885-019-6311-z","article-title":"The clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer","volume":"19","author":"Wang","year":"2019","journal-title":"BMC cancer"},{"key":"R2-20251114","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1634\/theoncologist.2019-0427","article-title":"Lymph node imaging in patients with primary breast cancer: concurrent diagnostic tools","volume":"25","author":"Marino","year":"2020","journal-title":"Oncologist"},{"key":"R3-20251114","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1200\/JCO.2004.01.175","article-title":"CNS metastases in breast cancer","volume":"22","author":"Lin","year":"2004","journal-title":"J Clin Oncol"},{"key":"R4-20251114","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1148\/rg.347130141","article-title":"To do or not to do: axillary nodal evaluation after ACOSOG Z0011 Trial","volume":"34","author":"Humphrey","year":"2014","journal-title":"Radiographics"},{"key":"R5-20251114","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13550-024-01094-6","article-title":"Biodistribution and dosimetry of (177)Lu-DOTA-IBA for therapy of bone metastases","volume":"14","author":"Li","year":"2024","journal-title":"EJNMMI Res"},{"key":"R6-20251114","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/RLU.0000000000004634","article-title":"Safety and efficacy of 68 Ga- or 177 Lu-labeled DOTA-IBA as a novel theranostic radiopharmaceutical for bone metastases : a phase 0\/I study","volume":"48","author":"Qiu","year":"2023","journal-title":"Clin Nucl Med"},{"key":"R7-20251114","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1021\/acs.molpharmaceut.2c00978","article-title":"Lutetium177-labeled DOTA-Ibandronate: a novel radiopharmaceutical for targeted treatment of bone metastases","volume":"20","author":"Wang","year":"2023","journal-title":"Mol Pharm"},{"key":"R8-20251114","doi-asserted-by":"crossref","first-page":"1027792","DOI":"10.3389\/fonc.2022.1027792","article-title":"Preparation, biological characterization and preliminary human imaging studies of (68)Ga-DOTA-IBA","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"R9-20251114","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1097\/RLU.0000000000005415","article-title":"Incidental uptake of 68 Ga-DOTA-IBA in prostate adenocarcinoma","volume":"49","author":"Liu","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R10-20251114","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1097\/RLU.0000000000005462","article-title":"Increased uptake of 68 Ga-DOTA-IBA in multiple subcutaneous metastases of prostate cancer","volume":"49","author":"Liu","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R11-20251114","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/RLU.0000000000005200","article-title":"68 Ga-DOTA-IBA uptake in breast cancer","volume":"49","author":"Xiang","year":"2024","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T13:00:43Z","timestamp":1763125243000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":11,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006066","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"type":"print","value":"0363-9762"},{"type":"electronic","value":"1536-0229"}],"subject":[],"published":{"date-parts":[[2025,7,29]]},"assertion":[{"value":"2025-04-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}